PyInvesting

Market research

MANGALAM.NSE Mangalam Drugs & Organics Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
482M
P/E ratio
Not available
Analyst target
Not available
Dividend yield
Not available
Beta
0.27

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

Mangalam Drugs & Organics Limited is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.

From a valuation standpoint, the stock is 89.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.5.

Mangalam Drugs & Organics Limited's total revenue sank by 71.3% to $887M since the same quarter in the previous year.

Its net income has dropped by 48.3% to $64M since the same quarter in the previous year.

Finally, its free cash flow fell by 0.0% to $81M since the same quarter in the previous year.

Based on the above factors, Mangalam Drugs & Organics Limited gets an overall score of 2/5.